The novel anticancer aryl-ureido fatty acid CTU increases reactive oxygen species production that impairs mitochondrial fusion mechanisms and promotes MDA-MB-231 cell death
Publication Details
Tam, S.,
Umashankar, B.,
Rahman, K.,
Choucair, H.,
Rawling, T.,
&
Murray, M.
(2024).
The novel anticancer aryl-ureido fatty acid CTU increases reactive oxygen species production that impairs mitochondrial fusion mechanisms and promotes MDA-MB-231 cell death.
International Journal of Molecular Sciences, 25 (19).
Abstract
Cancer cell mitochondria are functionally different from those in normal cells and could be targeted to develop novel anticancer agents. The aryl-ureido fatty acid CTU (16({[4-chloro-3- (trifluoromethyl)phenyl]-carbamoyl}amino)hexadecanoic acid) is the prototype of a new class of targeted agents that enhance the production of reactive oxygen species (ROS) that disrupt the outer mitochondrial membrane (OMM) and kill cancer cells. However, the mechanism by which CTU disrupts the inner mitochondrial membrane (IMM) and activates apoptosis is not clear. Here, we show that CTU-mediated ROS selectively dysregulated the OMA1/OPA1 fusion regulatory system located in the IMM. The essential role of ROS was confirmed in experiments with the lipid peroxyl scavenger α-tocopherol, which prevented the dysregulation of OMA1/OPA1 and CTU-mediated MDA-MB-231 cell killing. The disruption of OMA1/OPA1 and IMM fusion by CTU-mediated ROS accounted for the release of cytochrome c from the mitochondria and the activation of apoptosis. Taken together, these findings demonstrate that CTU depolarises the mitochondrial membrane, activates ROS production, and disrupts both the IMM and OMM, which releases cytochrome c and activates apoptosis. Mitochondrial-targeting agents like CTU offer a novel approach to the development of new therapeutics with anticancer activity
Keywords
aryl-ureido fatty acids, anticancer agent, mitochondrial membrane, reactive oxygen species, mitochondrial fission and fusion
Link to Publisher Version (URL)
